Bluebird Bio Inc. (NASDAQ:BLUE)‘s stock had its “buy” rating reissued by analysts at JPMorgan Chase & Co. in a note issued to investors on Monday.
Other equities research analysts also recently issued research reports about the stock. BTIG Research reissued a “buy” rating and set a $72.00 price objective on shares of Bluebird Bio in a research report on Sunday, September 11th. Goldman Sachs Group Inc. reaffirmed a “buy” rating and issued a $135.00 target price on shares of Bluebird Bio in a research report on Thursday, September 8th. Leerink Swann reaffirmed a “buy” rating on shares of Bluebird Bio in a research report on Friday, September 9th. Piper Jaffray Cos. set a $95.00 target price on shares of Bluebird Bio and gave the company a “buy” rating in a research report on Thursday, September 8th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $85.00 target price (down previously from $105.00) on shares of Bluebird Bio in a research report on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have given a buy rating to the company. Bluebird Bio presently has a consensus rating of “Buy” and a consensus target price of $82.82.
Bluebird Bio (NASDAQ:BLUE) traded up 2.32% on Monday, hitting $63.95. 505,529 shares of the stock traded hands. The firm’s 50 day moving average is $56.23 and its 200 day moving average is $52.68. Bluebird Bio has a 52 week low of $35.37 and a 52 week high of $94.61. The stock’s market cap is $2.39 billion.
Bluebird Bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.59) by $0.48. Bluebird Bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. The company had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.82 million. During the same period in the prior year, the company earned ($1.18) EPS. The firm’s revenue was up 17.4% on a year-over-year basis. Equities analysts anticipate that Bluebird Bio will post ($7.05) earnings per share for the current year.
In other Bluebird Bio news, insider Eric Sullivan sold 416 shares of the stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $67.00, for a total value of $27,872.00. Following the completion of the sale, the insider now owns 5,891 shares in the company, valued at $394,697. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 3.50% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP bought a new stake in Bluebird Bio during the first quarter worth about $51,095,000. BlackRock Inc. boosted its stake in Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock worth $194,000 after buying an additional 3,533 shares in the last quarter. California State Teachers Retirement System boosted its stake in Bluebird Bio by 2.2% in the second quarter. California State Teachers Retirement System now owns 77,687 shares of the company’s stock worth $3,363,000 after buying an additional 1,682 shares in the last quarter. Vanguard Group Inc. boosted its stake in Bluebird Bio by 14.2% in the second quarter. Vanguard Group Inc. now owns 2,680,871 shares of the company’s stock worth $116,055,000 after buying an additional 333,396 shares in the last quarter. Finally, Swiss National Bank boosted its stake in Bluebird Bio by 10.6% in the second quarter. Swiss National Bank now owns 59,707 shares of the company’s stock worth $2,585,000 after buying an additional 5,700 shares in the last quarter.
About Bluebird Bio